This review looked at whether medications similar to the GLP-1 hormone can improve liver health for people with type 2 diabetes (T2D) and fatty liver disease. It found that these medications can improve liver health and reduce fat in the liver.

This study compared metformin (Glucophage) to insulin for women with diabetes during pregnancy. It found that metformin was equally good at preventing high blood sugar, but led to less hypoglycemia (dangerously low blood glucose), less weight gain, and fewer cesarean sections.

This study looked at whether myoinositol and α-lactalbumin can benefit women with diabetes during pregnancy. It found that these supplements may reduce insulin resistance and pre-term birth in these women.

This study reviewed the effectiveness of resistance exercise in patients with rheumatoid arthritis (RA). The data showed that resistance exercise can significantly improve disease activity in these patients.

This study looked at how weekly semaglutide (Ozempic) affected patients with type 2 diabetes (T2D) in a real-world setting. It found that semaglutide improved blood sugar control compared to the treatments patients were already taking.

This study compared the effectiveness and safety of biphasic insulin aspart 30 (BIAsp 30; NovoMix 30) alone or with metformin (Glucophage), in patients with inadequately controlled type 2 diabetes (T2D). The authors concluded that combined therapy may be preferred in patients with high cardiovascular risk and/or a body mass index (BMI; a measure of body weight in relation to height) of 26 kg/m² or less.

This study looked at whether oat bran consumption benefited women with diabetes during pregnancy. It found that adding oat bran to the recommended diet improved blood sugar levels in these women.

This review looked at levels of lipoprotein A (LpA), in people with type 2 diabetes (T2D). It found that people with higher levels LpA in their blood were more likely to have kidney disease.

This study examined the effectiveness of adding henagliflozin (SHR3824) to metformin (Glucophage) in patients with uncontrolled type 2 diabetes (T2D). The authors concluded that the addition of 5 mg or 10 mg of henagliflozin to metformin was well-tolerated and effective in these patients. 

This study looked at the ertugliflozin (Steglatro) for patients with type 2 diabetes (T2D) and heart disease. It found that ertugliflozin improved both blood glucose control, body weight, and blood pressure.